BioMarin Pharma (NASDAQ: BMRN) announced data analysis for Kyndrisa demonstrating consistent evidence of efficacy in comparable patients across three randomized ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE